Carbapenem stewardship program in a French university children's hospital.
Adolescent
Anti-Bacterial Agents
/ administration & dosage
Antimicrobial Stewardship
/ methods
Carbapenems
/ administration & dosage
Child
Child, Preschool
Enterobacteriaceae Infections
/ drug therapy
Female
France
Hospitals, Pediatric
/ organization & administration
Humans
Infant
Infant, Newborn
Male
Program Development
/ methods
Retrospective Studies
Antimicrobial resistance
Antimicrobial stewardship program
Carbapenemases
Carbapenems
Extended-spectrum beta-lactamase-producing enterobacteriaceae
pediatric
Journal
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
19
01
2021
revised:
19
05
2021
accepted:
03
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
entrez:
23
10
2021
Statut:
ppublish
Résumé
Carbapenems, last-resort antibiotics, are widely used as first-line treatment in patients carrying extended-spectrum beta-lactamases (ESBL) Enterobacteriaceae, including in a pediatric setting. We aimed to implement an antibiotic stewardship program (ASP) to improve the use of carbapenems. We implemented an ASP at the Bordeaux Children's University Hospital with 6-month audits on prescribing practice before and after an intervention (revision of antibiotic treatment protocols, a half-day educational session with feedback of the first study period). The number of carbapenem prescriptions was analyzed and two criteria were used to assess conformity of the indication for carbapenem prescription and conformity of the reassessment. A logistic regression was used to assess the overall compliance of carbapenem prescriptions over the two periods adjusted for ESBL carriage. A total of 57 patients were included with 37 carbapenem prescriptions before the intervention and 23 after. Overall carbapenem consumption decreased from 0.54 prescriptions per 100 admissions to 0.32 (p = 0.06). Conformity increased during the study for indication (46-87%, p = 0.004) and for reassessment (48-78%, p = 0.04) and was significantly associated with the second study period, after adjustment for ESBL carriage. Our intervention contributed to a significant improvement in the compliance to indications for carbapenem indication and in the reassessment of the prescription.
Identifiants
pubmed: 34686425
pii: S0929-693X(21)00199-8
doi: 10.1016/j.arcped.2021.10.004
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-625Informations de copyright
Copyright © 2021. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.